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Abstract
Natural course of prolactinomas after menopause is not fully elucidated. The aim of this study was to compare recurrence rate
after cabergoline withdrawal in premenopausal vs. postmenopausal women with microprolactinoma. Sixty-two women with
microprolactinoma treated with cabergoline for at least 1 year and followed for 2 years after drug withdrawal were retrospectively
selected. Patients were divided into two groups: 48 patients stopped cabergoline before menopause (BPRE^ group), while 14 after
menopause (BPOST^ group). Recurrence was defined by prolactin levels above normal, confirmed on two occasions. Overall,
39/62 women relapsed. Patients who relapsed apparently had higher prolactin before withdrawal (median 216.2, range 21.2–
464.3 mIU/L) compared with those in long-term remission (94.3, 29.7–402.8 mIU/L; p < 0.05), and the risk of recurrence seemed
lower in POSTwomen (4/14, 29%) than in PRE ones (35/48, 73%, p < 0.005, OR 0.149, 95% CI 0.040–0.558). However, none
of the factors (prolactin before withdrawal, menopausal status, treatment duration, complete adenoma regression) showed a
correlation with recurrence risk in multivariate analysis. The best strategy able to optimize CBG treatment and withdrawal’s
outcomes is still to be defined in microprolactinomas. Postmenopausal status cannot reliably predict long-term remission, and
follow-up is needed also in women of this age.
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Introduction
Microprolactinomas are the most common pituitary adenomas in
young women [1], manifesting with oligomenorrhea or amenor-
rhea, infertility, and galactorrhea. Dopamine agonists, in particu-
lar, cabergoline (CBG), are the first-choice treatment, aiming to
lower prolactin levels (PRL), reduce adenoma size, and restore
gonadal function [2, 3]. Pathogenesis, natural history, and ideal
treatment, in terms of duration or criteria for drugwithdrawal, are
not fully understood for this subtype of pituitary tumor. There is
evidence that estrogens can stimulate normal and neoplastic
lactotrophs’ growth in vitro and in vivo animal models [4, 5];
however, in humans, evidence is limited to a few studies which
have shown a positive effect of the postmenopausal state on the
course of disease, with spontaneous and progressive reduction of
PRL and adenoma size observed in untreated women, and rare
cases of hyperprolactinemia recurrence [6–9]. However, drawing
definitive conclusions is difficult for these studies, because pa-
tients included were heterogeneous in regard to the etiology of
hyperprolactinemia (microprolactinomasvs.macroprolactinomas
vs. idiopathic hyperprolactinemia), to the previously employed
treatment (surgery vs. medical treatment vs. no treatment) and to
the specific drug administered (CBG vs. bromocriptine vs. other
dopamine agonists). Also in normoprolactinemic women, some
authors showed a trend of spontaneous reduction in PRL after
cessation of ovarian activity [10–12], but other studies did not
confirm this finding [13].
According to the 2011 Endocrine Society guidelines [2],
drug withdrawal may be attempted in women with
microprolactinoma when menopause occurs, since the effect
of hyperprolactinemia on the hypothalamus-pituitary-gonadal
axis is no longer a concern in this period of life, even if long-
term follow-up for tumor regrowth is recommended.
However, most recent data about the possible direct adverse
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effects of hyperprolactinemia on bone [14, 15], glucose and
lipid metabolism [16], cardiovascular risk profile [17, 18], and
quality of life [19–21] may be of concern in postmenopausal
women and may deserve consideration when deciding to dis-
continue dopaminergic treatment.
Which clinical, biochemical, and radiological features, if any,
can reliably predict long-term outcome in microprolactinomas
remains unclear [22–26]; a better understanding of these aspects
is important to help optimize the management of patients with
microprolactinoma and may provide an insight in the underlying
pathogenetic mechanisms. In order to verify if estrogenic expo-
sure plays a role in microprolactinoma’s recurrence, the aims of
the present study were: (1) to analyze clinical, biochemical, and
radiological characteristics of patients with microprolactinomas
in long-term remission after CBG withdrawal, compared with
those experiencing hyperprolactinemia recurrence; (2) to com-
pare recurrence rates after CBG withdrawal in premenopausal
and in postmenopausal women; (3) to investigate which factors,
including the postmenopausal status, were able to predict the
long-term outcomes in both the whole study population and
specifically in the postmenopausal group.
Subjects and Methods
Inclusion and Exclusion Criteria
Women with a diagnosis of microprolactinoma treated be-
tween 1990 and 2015 in our institute were retrospectively
investigated in this study. In order to overcome heterogeneity
in clinical practice and to select a group of patients whose
management had been adherent to current guidelines [2, 3],
we established the following selection criteria.
Inclusion criteria:
– female patient with microprolactinoma;
– continuous CBG treatment for ≥ 12 months;
– visible adenoma shrinkage on treatment;
– normal PRL levels before CBG withdrawal;
– the patient had a period of CBG withdrawal and a subse-
quent follow-up of 24 months.
Exclusion criteria:
– previous surgery and/or radiotherapy of the sellar region;
– multiple endocrine neoplasia (MEN) syndrome, for the
well-known peculiarities of prolactinomas’ behavior as-
sociated with this condition (greater aggressiveness and
resistance to dopamine agonists) [27];
– the patient stopped CBG for pregnancy;
– the patient was taking interfering drugs after CBG with-
drawal (e.g., antidepressants, estroprogestinic therapy).
Definitions and Procedures
The diagnosis of microprolactinoma was based on the pres-
ence of typical signs and symptoms (menstrual abnormalities,
infertility, galactorrhea), PRL ≥ 530 mIU/L (25 mcg/L), and
evidence of a pituitary adenoma < 10 mm in the largest diam-
eter on magnetic resonance imaging (MRI) or computed to-
mography (CT) scanning of the sellar region with and without
contrast enhancement.
At the time of diagnosis, pituitary function was assessed
with basal pituitary hormone levels, followed by dynamic
testing if clinically appropriate. In all patients, renal failure,
primary hypothyroidism, acromegaly, and other secondary
causes of elevated PRL (e.g., medications, pregnancy), as well
as macroprolactinemia were excluded.
Patients were divided into two groups according to their
ovarian status at the moment of CBG withdrawal: patients
who stopped treatment before menopause were included in
PRE group, while patients who stopped CBG after menopause
had occurred were included in the POST group. Menopause
was diagnosed after 12 consecutive months of amenorrhea in
normoprolactinemic women, in conjunction with raised FSH
and low estrogen levels.
We followed up patients for 24 months after drug with-
drawal. PRL was assessed at 3, 6, 12, 18, and 24 months.
MRI scanning was performed after 1 year in all women, or
at any time if a significant raise in PRL was observed.
Recurrence of hyperprolactinemia was defined by serum
PRL ≥ 530 mIU/L confirmed on two occasions.
The study was approved by the Milan Area 2 Ethical
Committee, and informed consent was obtained from all indi-
vidual participants included in the study.
Assay Methods
Serum PRL was measured by an electrochemiluminescence
sandwich immunoassay (ECLIA, Elecsys Prolactin II, Roche,
Mannheim, Germany; for the instrument’s calibration, the 3rd
World Health Organization IRP 84/500 was used).
Macroprolactinemia was excluded with polyethylene gly-
col precipitation (Sigma-Aldrich Inc., Milan, Italy), and re-
sults were expressed as percentage of PRL recovery; a recov-
ery ≥ 50% was considered indicative of predominantly mono-
meric PRL; recovery < 40% was classified as predominantly
high molecular weight forms; and recovery between 40 and
50% as indeterminate, and the latter two cases were not in-
cluded in the study.
Statistical Analysis
Data were extracted from medical records stored in our de-
partment and collected using Microsoft Office Excel software
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(version 2007). Analysis was performed with IBM SPSS
Statistics (version 25).
We performed a Shapiro-Wilk test to define distributions
(normal and nonnormal) of quantitative variables.
Quantitative parametric variables were expressed as mean ±
standard deviation (SD), quantitative nonparametric variables
as median and range, and qualitative variables as absolute and
relative frequencies. Fisher’s exact test was used to compare
number of patients in 2 × 2 contingency tables. Paired or un-
paired Student’s t test was performed to compare different
variables when data were normally distributed. Otherwise, a
nonparametric Mann-Whitney test was used. Univariate and
multivariate analyses were performed by a logistic regression
method. Correlation for continuous variables was assessed by
Spearman’s rank correlation test. Values of p < 0.05 were con-
sidered statistically significant.
Results
Patients’ Selection
Between 1990 and 2015, 282 patients with microprolactinoma,
of whom 252 women, were followed at our institute; until 2006,
when the Pituitary Society’s guidelines were released, clinical
management of patients with microprolactinoma was found to
be heterogeneous and often not to fit actual recommendations; in
particular, in guiding dopamine agonists’ dose titration and
subsequent drug withdrawal, greater importance was given to
clinical and radiological response (restoration of regular menses
and fertility, disappearance of galactorrhea, adenoma shrinkage),
rather than to normalization of PRL levels. In order to overcome
these limits, we applied inclusion and exclusion criteria which
led to the selection of a homogeneous group of 62 patients
(Fig. 1).
In more detail, we excluded patients who had never re-
ceived CBG (n = 46), those who stopped therapy after a few
months for intolerance and were consequently treated with
bromocriptine or estroprogestinic therapy (n = 2), and those
who underwent surgery before medical therapy (n = 1) or be-
came drug resistant (n = 3). Furthermore, 16 women were lost
to follow-up, two patients were on potentially interfering drug
therapy after CBG withdrawal, and one was diagnosed with
MEN 1. Twelve women discontinued CBG after adequate
clinical and radiological response but with still elevated PRL
levels (median PRL decrease from baseline on CBG therapy
57%, range 42–86%; median PRL levels at withdrawal 806,
range 657–1314 mIU/L).
Among the remaining 107 patients, 26 stopped CBG for
pregnancy; 8 have recently stopped CBG but have not com-
pleted the 24-month follow-up; the others have not stopped
CBG yet for different reasons: 13 showed poor treatment com-
pliance and took CBG discontinuously; 21 have been treated
for less than 3 years; in 16, no volume reduction was docu-
mented during medical treatment and in 9, prolactin levels did
not normalize (CBG dose was increased up to 3 mg per week
Fig. 1 Flow chart showing the
process of patients’ selection
(CBG = Cabergoline, MEN 1 =
Multiple Endocrine Neoplasia
syndrome type 1, PRL = Prolactin
levels)
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in these patients); 8 patients were desirous of pregnancy and
decided to continue CBG until pregnancy was ascertained; 6
are actually undergoing CBG tapering before discontinuation.
Study Population’s Characteristics and Risk
of Hyperprolactinemia Recurrence
The remaining 62 patients represent the study population.
Somewomen had received one or more different dopamine
agonists before CBG.
Complete adenoma regression was documented in 19 out
of 62 women before drug withdrawal (31%). For the remain-
ing patients, a median 35% decrease from baseline adenoma
size was observed during the CBG treatment (range 12–71%,
corresponding to a median variation in maximum diameter of
− 1.75 mm, range − 0.7 to − 5 mm).
Prolactin levels’ decrease during the CBG treatment ranged
from 69 to 98% of baseline values. Complete clinical and
biochemical characteristics are reported in Table 1.
Overall, recurrence of hyperprolactinemia was observed in
39 out of 62 women (63%). Twenty out of 39 women relapsed
within 3 months after CBGwithdrawal and 35/39 (90%) with-
in 12 months. Tumor regrowth was not observed in any of our
patients.
Patients who relapsed were not different from those in
long-term remission with regard to PRL levels at diagnosis,
treatment duration (p = 0.074), cumulative CBG dose (p =
0.223), previous use of other dopamine agonists, and frequen-
cy of adenoma disappearance before withdrawal. The only
two features which differentiated patients in the two outcome
groupswere PRL levels before withdrawal, whichwere higher
in case of hyperprolactinemia recurrence (median 216.2,
range 21.2–464.3 mIU/L, vs. median 94.3, range 29.7–
402.8 mIU/L for the remission group; p = 0.049), and
prevalence of postmenopausal women (10/23 in the remission
group vs. 4/39 in the recurrence group, p < 0.01).
Comparison of Premenopausal and Postmenopausal
Women
Women were then divided into the two groups according to
their ovarian status at the moment of CBG withdrawal: 48
patients restored regular menstrual cycles during the CBG
treatment and were included in the PRE group; the remaining
14 patients had gone through menopause before CBG with-
drawal and were then included in the POST group. The char-
acteristics of the two groups are summarized in Table 1. No
woman in the POST group received hormonal replacement
therapy after menopause because of the lack of clinical
indications.
Patients who stopped CBG after menopause had a signifi-
cantly lower risk of recurrence compared with patients who
stopped before menopause (4/14, 29%, vs. 35/48, 73%; p =
0.004, OR 0.149, 95% CI 0.040–0.558).
PRL at diagnosis, previous use of other dopamine agonists,
CBG dose per week, PRL before drug withdrawal, and fre-
quency of prolactinoma disappearance at the last MRI were
not different in the two groups.
As expected, the PRE group and the POST group were sig-
nificantly different for age at diagnosis (median 28, range 15–43,
vs. median 43, range 24–53 years old respectively, p < 0.001)
and for age at withdrawal (median 31, range 20–49, vs. median
51, range 46–56 years old respectively, p < 0.001).
Postmenopausal patients were treated for a longer time (median
5, range 2–25 years) than premenopausal ones (median 3, range
1–11; p = 0.001), and consequently received higher cumulative
CBG doses (median 130, range 52–1300 mg, vs. median 52,
range 13–390 mg in PRE patients, p = 0.007).
Table 1 Clinical and biochemical features of the study patients (column BALL^) and comparison between women in premenopausal status (PRE) and
postmenopausal status (POST) at the time of CBG withdrawal
Group ALL PRE POST p value (PRE vs. POST)
Age at diagnosis, median (range) (years) 29 (15–53) 28 (15–43) 43 (24–53) < 0.001
Maximum diameter, mean ± SD (mm) 5.7 ± 1.6 5.6 ± 1.6 6.3 ± 1.7 ns
PRL at diagnosis, median (range) (mIU/L) 2056 (933–4537) 2014 (933–4537) 2120 (1102–4070) ns
Other dopamine agonists prior to CBG (n) 21/62a 16/48 5/14 ns
Treatment duration, median (range) (years) 3 (1–25) 3 (1–11) 5 (2–25) 0.001
CBG dose per week, median (range) (mg) 0.5 (0.25–1.5) 0.5 (0.25–1.5) 0.5 (0.25–1) ns
Cumulative CBG dose, median (range) (mg) 78 (13–1300) 52 (13–390) 130 (52–1300) 0.007
Age at withdrawal, median (range) (years) 34 (20–56) 31 (20–49) 51 (46–56) < 0.001
PRL before withdrawal, median (range) (mIU/L) 161 (21–464) 148 (21–464) 165 (42–403) ns
Prolactinoma disappearance before withdrawal (n) 19/62 14/48 5/14 ns
a Sixteen treated with bromocriptine, 1 with lysuride, 2 with dihydroergocryptine, 1 with quinagolide, and 1 with dihydroergocryptine followed by
bromocriptine
PRL, prolactin levels; CBG, cabergoline
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Predictive Factors for Long-Term Outcomes
We had previously found that treatment duration was not dif-
ferent in the two outcomes (hyperprolactinemia recurrence vs.
long-term remission) in our population. However, in order to
further investigate whether longer treatment duration and
higher cumulative CBG doses could have influenced the
higher remission rate in postmenopausal women, we per-
formed binomial logistic regression for these two independent
variables. Univariate analysis confirmed lack of association
between hyperprolactinemia recurrence and both treatment
duration (p = 0.226) and cumulative CBG dose (p = 0.283).
Additionally, no association was found between tumor disap-
pearance before withdrawal and probability of long-term re-
mission (p = 0.427) in univariate analysis, as well.
Given that the beneficial effects of menopause on
microprolactinomas are supposed to be due to a reduction of
circulating estrogens, we tested whether a correlation exists
between estradiol and prolactin. Median estradiol levels re-
sulted 35 (range 0–95) pg/mL before CBG treatment, 33 (0–
477) pg/mL on therapy, and 26 (5–217) pg/mL after with-
drawal. Again, we failed to find a correlation between the
two hormones’ levels at the three time points (before treat-
ment: rho = − 0.258, p = 0.318; on CBG treatment: rho = −
0.126, p = 0.681; after withdrawal: rho = 0.112, p = 0.703).
Finally, we tested which factors could predict recurrences
in microprolactinomas by a linear logistic regression analysis;
when multivariate analysis was performed, correlation of
microprolactinomas’ outcomes with PRL levels at withdrawal
(p = 0.054) and with the postmenopausal status (p = 0.054)
was not confirmed.
Postmenopausal Patients
Twenty-eight percent of women who stopped CBG after men-
opause relapsed. In this group of women, PRL at diagnosis
and before withdrawal, treatment duration, cumulative CBG
dose, previous use of other dopamine agonists, and frequency
of adenoma disappearance before withdrawal were not differ-
ent whether patients relapsed or remained in long term remis-
sion (data not shown).
Discussion
This study retrospectively analyzes the risk of hyperprolactinemia
recurrence in microprolactinomas after suspension of CBG, par-
ticularly comparing the effects of stopping the treatment before
and after menopause.
Overall, hyperprolactinemia recurrence occurred in 63% of
women, which fits the very variable data reported in the liter-
ature (from 7 to 69% [22, 23, 28–32]); given the well-known
stimulating effect of estrogens on prolactin secretion in vivo
and in vitro, we investigated if a physiological hypoestrogenic
state-like menopause could impact the success of CBG with-
drawal in microprolactinomas; however, neither the meno-
pausal status at withdrawal nor the other variables tested
(treatment duration, PRL before withdrawal, complete adeno-
ma regression) were associated with long-term outcomes in
our population. Furthermore, no association was found be-
tween the prolactin and estradiol levels.
In literature, many clinical, biochemical, and radiological
characteristics have been investigated as potentially predictive
factors for long-term remission in prolactinomas, like treat-
ment duration, complete tumor regression before withdrawal,
and nadir PRL reached during dopamine agonist treatment
[22, 25, 26, 33–35], and some were included by most recent
guidelines as criteria for drug withdrawal [2, 3].
The lack of association that we found between CBG with-
drawal’s outcomes and complete tumor regression, treatment
duration, or cumulative CBG doses is concordant with other
previously published research [23, 25, 33]. In particular, given
the unclear role of treatment duration on microprolactinomas’
outcomes, we decided to include in the present study patients
treated with CBG for at least one year, although most recent
guidelines [2, 3] recommend a 2–3-year treatment before drug
withdrawal. As stated above, we then verified that treatment
duration did not impact the risk of hyperprolactinemia recur-
rence in our population.
Two meta-analysis on this subject have recently been re-
leased [22, 34]. Hu et al. [22] found a hyperprolactinemia
recurrence rate of 60% in microprolactinomas treated with
CBG. Continuation of the CBG treatment for longer than
2 years was not associated with higher success rates, similar
to our results on treatment duration. However, Xia et al. in
their meta-analysis [34] affirmed the opposite, since they
found a higher remission rate when treatment was continued
for more than 24 months. Furthermore, both meta-analysis
found that a significant tumor volume reduction (i.e., ≥ 50%
decrease from baseline) was relevant to long-term outcome.
However, authors did not differentiate microprolactinomas
and macroprolactinomas in this respect. Additionally, in our
study we did not focus on the degree of tumor shrinkage, but
only compared complete tumor regression vs. adenoma per-
sistence, so these results are not easily comparable.
Interestingly, both meta-analyses found that a low CBGmain-
tenance dose (i.e., ≤ 0.5 mg per week) is associated with a
higher remission rate.
According to current literature [2, 6–8, 19, 36], dopamine ag-
onistwithdrawal can be considered safewhenmenopause occurs,
with low rates of hyperprolactinemia recurrence; however, only a
fewstudieshave specifically focusedonprolactinomas’outcomes
after menopause. Karunakaran et al. [7] found that, among men-
opausal women, 45% normalized PRL off treatment, compared
with only 7%ofwomenwith preserved ovarian function; howev-
er, patients in Karunakaran’s study were quite heterogeneous in
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regard to hyperprolactinemia etiology (idiopathic vs.
microprolactinoma) and to previous treatment (surgery vs. dopa-
mine agonists vs. no treatment); in fact, among postmenopausal
women,only7/11had receiveddopamineagonists,while twohad
undergone surgery.Touraine et al. [6] described a small groupof 4
women with microprolactinoma whose PRL spontaneously re-
duced off treatment after menopause. Mallea-Gil et al. followed
22 patients with microprolactinoma for a period between 4 and
192 months after CBG or bromocriptine suspension and found
that only two patients needed to restart treatment for increasing
PRL levels; among the remaining 20, a spontaneous reduction of
PRL and a high rate of tumor disappearance at MRI were found
[8]. In a recently published study from UK [9], Santharam et al.
found that among 16 postmenopausal womenwho stoppedmed-
ical treatment after menopause with normalized prolactin levels,
recurrence ratewas significantly lower than that inpremenopausal
onesandcomparablewith thatobserved inour study,31%. In their
study, no difference in terms of recurrence rate was observed ac-
cording to the adenoma size or drug used (bromocriptine vs.
cabergoline). Interestingly, an increase in adenoma volume after
treatment withdrawal was reported in two postmenopausal pa-
tients. PRL at 6–12 months off treatment was the only predictive
factor for long-term remission.
In our study, no factor could explain differences in the out-
comes of CBG withdrawal between premenopausal and post-
menopausal women. In fact, even though postmenopausal wom-
en had been treated with CBG for a longer time than premeno-
pausal patients, the treatment duration did not show any statistical
association with long-term outcome, as stated above. The two
groups of women were comparable for all other characteristics,
so one may suppose that the favorable outcome observed in
postmenopausal women could be due to hypoestrogenism.
Estrogen is a very well-known stimulus for PRL synthesis and
secretion. In fact, microprolactinomas are most frequently found
in young women in their fertile age (20–50 years old) [19]; in
animal models, ovariectomy causes a reduction in pituitary
lactotrophs’ size and number and a reduction in circulating pro-
lactin levels; these effects can be reversed by estrogen adminis-
tration [4]. In addition, it was shown that anti-estrogens reduce
PTTG expression in human pituitary tumors in vitro and sup-
press tumor growth in rats in vivo, concomitantly with reduced
PRL secretion [5]. However, in humans, evidence is limited; in
our study, between one quarter and one-third of postmenopausal
women relapsed and PRL showed no correlation with estradiol
levels, thus suggesting that other factors may stimulate
prolactinomas’ growth and secretion; for instance, whether other
neuro-endocrinological systems and molecules, which may
eventually modify after menopause, play a role in lactotrophs’
modulation is not known. Pathogenetic mechanisms for
microprolactinomas, including genetics, signaling pathways,
and local stimuli, are still far from being fully understood. In
our opinion, this may partly explain why, despite many efforts
to identify predictive factors for long-term outcomes in these
adenomas, clinical data are largely discordant and definitive con-
clusion can be hardly drawn yet.
The clinical implications of hyperprolactinemia recurrence
in menopause are not known. In fact, gonadal dysfunction is
no more a concern after menopause, so microprolactinomas
should not deserve dopaminergic treatment unless tumor re-
growth is observed. However, possible effects of
hyperprolactinemia on bone loss [14, 37], insulin resistance,
dyslipidemia [16, 38, 39], cardiovascular risk [17, 18, 40], and
quality of life [19–21] could be of some importance in this
group of women; long-term follow-up is recommended at
least until all these aspects are fully elucidated.
Our study has several strengths. We focused on current
management strategies for prolactinomas, including only pa-
tients treated with CBG and excluding those who had under-
gone surgical treatment or radiotherapy, that are nowadays
limited to resistant prolactinomas; in this way, we tried to
select a homogeneous group of women with regard to
hyperprolactinemia etiology and treatment employed, and this
represents a novelty compared with previous studies on this
subject. On the other side, our study has some limitations:
first, its retrospective design. The sample size is quite small,
however comparable with that of previously published re-
search on prolactinomas in postmenopausal women, and we
recognize that this could have partly influenced the negative
results. Another limitation is the short follow-up time; even if
it is well-known that most patients relapse within the first year
after drug withdrawal [25, 33], longer time may be needed to
better understand prolactinoma’s natural course.
In conclusion, CBG is an effective treatment for
microprolactinomas, but the best strategy in order to optimize
outcomes after drug withdrawal is still to be defined. Despite
the supposed st imulatory effect of estrogens on
microprolactinomas, a physiological hypoestrogenic state-
like menopause is not able to predict remission and nearly a
third of postmenopausal women relapse. For this reason, we
believe that, if a trial of CBG withdrawal is attempted, mon-
itoring for hyperprolactinemia recurrence is necessary also in
older women.
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